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the original work isObjective: Few data describe antiretroviral treatment (ART)-related adverse events
when treatment is initiated at CD4þ cell counts more than 350 cells/ml. We compared
rates of laboratory-defined adverse events (LDAEs) according to CD4þ cell count at ART
initiation.
Design: Analysis of on-going cohort study.
Methods: ART-naive persons initiating ART from 2000 to 2010 were included. Chi-
square, analysis of variance (ANOVA) and Kruskal–Wallis tests compared character-
istics among those starting ART with a CD4þ cell count of 350 or less, 351–499 and at
least 500 cells/ml. Time-updated Poisson regression compared rates of LDAE in the three
CD4þ cell strata. Cox proportional hazard models compared risk of ART discontinu-
ation.
Results: Nine thousand, four hundred and six individuals were included: median age
37 years, 61% white, 80%men, median viral load 4.8 log copies/ml. Four hundred and
forty-seven (4.9%) and 1099 (11.7%) started ART with a CD4þ cell count at least 500
and 351–499 cells/ml, respectively. One thousand, two hundred and eighty-three
(13.6%) patients experienced at least one LDAE. The rate of LDAE did not differ
between those starting ART with a CD4þ cell count 351–499 and less than 350 cells/ml
[relative rate 0.90, 95% confidence interval (CI) 0.74–1.09)], but an increased risk of
ART discontinuation was observed (hazard ratio 1.58, 95% CI 1.10–2.27). Those
starting ART at CD4þ cell count at least 500 cells/ml had an increased rate of LDAE
(relative rate 1.44, 95% CI 1.13–1.82) but were not more likely to discontinue ART
(hazard ratio 1.15, 95% CI 0.64–2.09).ippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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1334 AIDS 2014, Vol 28 No 9Conclusion: This study demonstrates the need to consider ART-related toxicities when
initiating therapy at CD4þ cell counts at least 500 cells/ml. Whilst evidence from
randomized controlled trials is awaited, the timing of ART initiation in terms of benefits
and risks of ART remains an important question.
 2014 Wolters Kluwer Health | Lippincott Williams & WilkinsAIDS 2014, 28:1333–1339Keywords: biological markers, CD4þ lymphocyte count, drug toxicity,
HAART, HIVIntroduction
The impact of antiretroviral therapy (ART) on viral
transmission [1] and pragmatic programmatic recom-
mendations have led to several HIV treatment guidelines
committees now recommending ART at CD4þ cell
counts more than 350 cells/ml [2–4]. Although public
health benefits of earlier ART have recently been
reported by the HPTN 052 study [1,5] and from
observational studies within HIV endemic communities
in Kwa-Zulu Natal [6], there remains insufficient
randomized evidence on the risk:benefit ratio for the
individual to support a shift to earlier ART initiation [7].
Currently, randomized controlled trial (RCT) evidence
demonstrates a survival benefit of initiating ARTat CD4þ
cell count of 350 cells/ml or less compared with deferring
to lower CD4þ cell count levels [8]. Well designed cohort
studies have also shown morbidity and mortality benefits
of ARTat CD4þ cell counts more than 350 cells/ml with
these effects appearing enhanced in the presence of
comorbidities, coinfections and advancing age [9,10].
Other analyses, however, have not demonstrated clear
survival benefits for asymptomatic HIV-positive indivi-
duals with CD4þ cell counts more than 500 cells/ml [11],
and as such, possible survival benefits must be balanced
against potential ART toxicities. It is hoped that the
START and TEMPRANO trials (RCTs to investigate
the risks and benefits to an individual of early ART
initiation) will definitively address this particular question,
but these will not report until 2015 [12,13]. In the
meantime, data from observational cohorts provide
valuable direction.
The UK Collaborative HIV Cohort (CHIC) Study is an
observational study collecting data from many of the UK’s
largest HIV treatment centres [14]. We sought to
determine the relative risk of developing severe (grade
3/4) [15] laboratory-defined adverse events (LDAEs) and
rates of ART discontinuation among individuals with
CD4þ cell counts of 350 or less, 351–499 and at least
500 cells/ml at ART initiation.Materials and methods
Individuals were included in this study if they initiated
ART between 2000 and 2010 at a UK CHIC centre thatpincott Williams & Wilkins. Unauthoprovided laboratory data. Those excluded were pregnant
women, those with a viral load less than 50 copies HIV
RNA/ml at ART initiation and those without at least one
CD4þ cell count, viral load or laboratory measurement
during follow-up. Pregnancy was established through
linkage between the UK CHIC and National Study of
HIV in Pregnancy and Childhood (NSHPC) databases
[16]. Eligible individuals were followed until the date last
seen at a UK CHIC centre or the earliest of drop-out of
follow-up for at least 18 months; discontinuation of ART
for at least 1 month; transfer to a centre not providing
laboratory data; pregnancy.
LDAEs were defined as grade 3/4 adverse events [15] for
any of alanine transaminase (ALT); aspartate transaminase
(AST); alkaline phosphatase (ALP); albumin; creatinine;
haemoglobin; platelets; amylase; cholesterol; glucose.
Bilirubin was not considered a LDAE so as to exclude
atazanavir-induced hyperbilirubinaemia. ART discon-
tinuation was defined as stopping all ART for at least
1 month.
Statistical analysis
Baseline characteristics according to CD4þ cell count at
ART start were compared using Chi-square and analysis
of variance (ANOVA) or Kruskal–Wallis tests. Poisson
regression compared LDAE rates according to CD4þ cell
count at ART initiation, censoring follow-up at first
LDAE. In sensitivity analyses, we excluded those with
hepatitis B virus (HBV) or hepatitis C virus (HCV)
coinfection and those who commenced nevirapine at
CD4þ cell counts more than 350 cells/ml, as this is now
contraindicated [17]. Further Poisson regression models
considered rates of LDAE that were likely to be related to
liver (ALT, AST, ALP, albumin), kidney (creatinine),
blood (haemoglobin, platelets) and other body systems
(amylase, cholesterol, glucose) separately. Individuals’
follow-up was split into 1-month intervals to create time-
updated covariates for viral load, ART regimen, HBV/
HCV status and time on ART. Time-independent
covariates were sex, exposure category, ethnicity, age
and previous experience of a LDAE at ART start. Time-
updated Cox proportional hazards models investigated
associations between CD4þ cell count and LDAE and the
risk of discontinuing ART considering the same
covariates as listed above as well as LDAE as a time-
updated covariate. To avoid including those whorized reproduction of this article is prohibited.
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of the SPARTAC study [18], we first only considered
discontinuations more than 1 year after the start of ART,
excluding those who attended main recruiting centres
for the SPARTAC study. In addition, the analysis was
performed considering all discontinuations occurring
after ART initiation (including those in the first year) but
restricting to the few centres that had no involvement in
the SPARTAC study. All analyses were performed in SAS
(version 9.3; SAS Institute Inc., Cary, North Carolina,
USA).Results
A total of 14 022 individuals commenced ARTafter 2000
in a centre that provided laboratory data. Of these, 3068
were excluded with viral load less than 50 copies/ml at
ART start, 534 had no follow-up, 363 had no CD4þ cell
count, 432 were pregnant and 219 had no laboratory
measures. Excluded individuals were more likely to be
female, of black or unknown ethnicity, and less likely to
have acquired HIV through sex between men.
Of 9406 patients, 7860 (83.6%), 1099 (11.7%) and 447
(4.8%) started ARTwith a CD4þ cell count of 350 or less,
351–499 and at least 500 cells/ml, respectively. Those
who started therapy with a CD4þ cell count more than
350 cells/ml were more likely to be white men who
acquired HIV through sex with men. HBV coinfection
was observed in 5.8% of those with a CD4þ cell count
at least 500 cells/ml compared with 2.6 and 3% in the
351–499 and 350 cells/ml or less groups, respectively
(P< 0.0001), whilst HCV coinfection was found in 4.5,
6.1 and 4.0%, respectively. Initial ART regimens differed
across CD4þ cell strata, with those in the at least
500 cells/ml group more likely to begin a protease
inhibitor-based regimen (P< 0.0001) (Table 1).
Rates of laboratory-defined adverse events
In 27 861 person-years of follow up, 1283 (13.6%)
individuals experienced a LDAE. There were 1094, 113
and 76 individuals with a LDAE in those starting ART
with a CD4þ cell count of 350 or less, 351–499 and at
least 500 cells/ml giving incidence rates [95% confidence
interval (95% CI)] of 4.6 (4.4–4.7), 4.9 (4.0–5.8) and 8.2
(6.4–10.1) per 100 person-years, respectively. Those who
started ARTwith a CD4þ cell count at least 500 cells/ml
had a higher rate of LDAE in both unadjusted and
adjusted analyses (relative rate, 95% CI 1.44, 1.13–1.82)
than in those commencing ART below 350 cells/ml
(Fig. 1a). No differences in rates of LDAE were seen
between those starting ARTat CD4þ cell count 351–499
or 350 cells/ml or less (relative rate, 95% CI 0.90 (0.74–
1.09). Excluding those with HBV/HCV coinfection or
those who started a nevirapine regimen with a CD4þ cell
count greater than 350 cells/ml did not alter our
conclusions (results not shown).Copyright © Lippincott Williams & Wilkins. UnautThose with a CD4þ cell count at least 500 cells/ml had a
greater risk of liver-related abnormalities after adjustment
for other factors (relative rate, 95% CI 1.45, 1.03–2.04).
There was no evidence of more liver, kidney, blood or
other LDAEs in the 351–499 cells/ml CD4þ cell count
group compared to the 350 cells/ml or less CD4þ cell
count group, in either unadjusted or adjusted analyses
(Fig. 1).
Discontinuation of antiretroviral therapy
Of 4583 individuals included in the analysis of ART
discontinuation after 1 year, 15.2, 14.2 and 18.6% of the
350 or less, 351–499 and at least 500 cells/ml CD4þ cell
count groups discontinued ART, respectively. Those
excluded from this analysis were more likely to be of
unknown ethnicity, to have started ART since 2008 and
to have a CD4þ cell count greater than 350 cells/ml.
Neither CD4þ cell count nor LDAEs were associated
with discontinuation of ART after 1 year (results not
shown).
In 1746 individuals attending centres not involved in
the SPARTAC study, 27.8, 28.6 and 31.3% of those
who started ART with a CD4þ cell count 350 or less,
351–499 and at least 500 cells/ml discontinued ART.
After adjustment for viral load, ART regimen, centre and
exposure group, an increased risk of discontinuation was
seen in those initiating ART with a CD4þ cell count
351–499 cells/ml (hazard ratio, 95% CI 1.59, 1.11–2.29)
but not in those with a CD4þ cell count at least
500 cells/ml (1.16, 0.64–2.09). LDAE was not associated
with ART discontinuation (0.77, 0.54–1.10) and did not
explain the increased risk of discontinuation in those
initiating ARTwith a CD4þ cell count 351–499 cells/ml,
as the CD4þ cell effect estimates remained unchanged
with the inclusion of LDAE in the model (hazard ratio,
95% CI 1.58, 1.10–2.27 351–499 cells/ml; 1.15, 0.64–
2.09 500 cells/ml).Discussion
Individuals starting ARTwith a CD4þ cell count at least
500 cells/ml had a 44% increased risk of grade 3/4 LDAE
compared with those initiating ART with a CD4þ cell
count 350 cells/ml or less. This increased risk was largely
explained by liver-test abnormalities. Higher rates of
discontinuation were observed in those starting ARTwith
a CD4þ cell count between 351 and 499 cells/ml in a
small group of centres, but presence of a LDAE was not
associated with ART discontinuation.
Despite adjusting for possible confounders, limitations
persist in our analysis. Firstly, the indication for starting
ART in those with a CD4þ cell count more than
350 cells/ml was not known. It is likely that many
individuals starting ART with CD4þ cell counts at least
500 cells/ml did so due to the presence of comorbidities,horized reproduction of this article is prohibited.
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Table 1. Patient characteristics at start of antiretroviral therapy, stratified by CD4R cell count at start of antiretroviral therapy.
CD4þ cell count at start of ART (cells/ml)
PAll <350 351–499 >500
N 9406 7860 1099 447
Age, median (IQR)
years 37 (32–43) 37 (32–43) 38 (32–44) 35 (30–42) 0.016a
Sex, n (%)
Male 7511 (79.9) 6147 (78.2) 958 (87.2) 406 (90.8) <0.0001b
Ethnicity, n (%)
White 5707 (60.7) 4586 (58.4) 787 (71.6) 334 (74.7) <0.0001b
Black African 2034 (21.6) 1861 (23.7) 131 (11.9) 42 (9.4)
Black other 473 (5.0) 404 (5.1) 52 (4.7) 17 (3.8)
Other/unknown 1192 (12.7) 1009 (12.8) 129 (11.7) 54 (12.1)
Mode of HIV acquisition, n (%)
Homosexual/bisexual 5666 (60.2) 4518 (57.5) 801 (72.9) 347 (77.6) <0.0001b
Heterosexual 3019 (32.1) 2739 (34.9) 212 (19.3) 68 (15.2)
Other/unknown 721 (7.7) 603 (7.7) 86 (7.8) 32 (7.2)
Hepatitis B coinfection, n (%)
No 5986 (63.6) 4913 (62.5) 775 (70.5) 298 (66.7) <0.0001b
Yes 290 (3.1) 235 (3.0) 29 (2.6) 26 (5.8)
Not tested 3130 (33.3) 2712 (34.5) 295 (26.8) 123 (27.5)
Hepatitis C coinfection, n (%)
No 6209 (66.0) 5107 (65.0) 784 (71.3) 318 (71.1) <0.0001b
Yes 398 (4.2) 311 (4.0) 67 (6.1) 20 (4.5)
Not tested 2799 (29.8) 2442 (31.1) 248 (22.6) 109 (24.4)
Viral load, median (IQR)
log10 copies/ml 4.8 (3.9–5.3) 4.8 (4.1–5.3) 4.4 (3.3–5.0) 4.3 (3.0–5.0) <0.0001
c
Year of starting ART, n (%)
2000–2003 2325 (24.7) 2035 (25.9) 160 (14.6) 130 (29.1) <0.0001b
2004–2007 3734 (39.7) 3257 (41.4) 339 (30.9) 138 (30.9)
2008–2010 3347 (35.6) 2568 (32.7) 600 (54.6) 179 (40.0)
Regimen type, n (%)
2 NRTI and PI (/r) 2221 (23.7) 1752 (22.3) 295 (26.8) 174 (38.9) <0.0001b
2 NRTI and PI 169 (1.8) 141 (1.8) 16 (1.5) 12 (2.7)
2 NRTI and NNRTI 6513 (69.2) 5559 (70.7) 718 (65.3) 236 (52.8)
3 NRTI 203 (2.2) 173 (2.2) 22 (2.0) 8 (1.8)
Other combination 300 (3.2) 235 (3.0) 48 (4.4) 17 (3.8)
Previous adverse event
Yes 825 (8.8) 679 (8.6) 98 (8.9) 48 (10.7) 0.31b
ART, antiretroviral therapy; IQR, interquartile range; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase
inhibitor; PI (/r), protease inhibitor (with/without ritonavir). P¼p-value of test of an overall difference between the 3 CD4þ cell count groups.
aAnalysis of variance (ANOVA) test.
bChi-square test.
cKruskal–Wallis test.which may independently cause laboratory abnormalities
that would have been classified as LDAEs in our analyses.
Although we were unable to capture much information
on the presence of comorbidities at ART initiation, we
did observe higher rates of HBV coinfection in those with
CD4þ cell counts at least 500 cells/ml; however, it must
be acknowledged that information on coinfection with
HBV or HCV was unavailable for a large proportion
of people. Adjustment for HBV/HCV coinfection and
LDAE prior to ART initiation, to try and account for
comorbidity, had no impact on the association between
CD4þ cell count and LDAE. A possible explanation for
the increased rate of liver-related LDAE is that HIV
seroconverters may be overrepresented in the group
initiating ART with a CD4þ cell count at least
500 cells/ml when elevated transaminases is common
[19,20]. Exclusion of those who started a nevirapine-
containing regimen at a CD4þ cell count more than
350 cells/ml did not alter our conclusions.pyright © Lippincott Williams & Wilkins. UnauthoOne concern of earlier ART initiation is the assumed
ambivalence of asymptomatic HIV-positive individuals
who start ARTwith high CD4þ cell counts who may be
less inclined to remain adherent to ART in the long term.
We saw no evidence that starting ARTwith a CD4þ cell
count more than 350 cells/ml was associated with more
treatment discontinuation after 1 year, but observed an
increased risk of discontinuation at any time with a CD4þ
cell count between 351 and 499 cells/ml in a small selection
of centres. Reasons for ART discontinuation are not well
reported in the UK CHIC study; however, this association
did not appear to be explained by presence of an LDAE.
The occurrence of grade 3/4 LDAEs was not indepen-
dently associated with increased discontinuation rates, an
observation in agreement with the recent publication of
the UK Register of HIV Seroconverters [21].
ART guidelines may be moving towards universal
treatment irrespective of CD4þ cell count. Therized reproduction of this article is prohibited.






































(b) Relative rate (95% CI) of liver-related LDAE according to CD4+

























































(e) Relative rate (95% CI) of blood-related LDAE according to CD4+
count at start of ART
Fig. 1. Rate of laboratory-defined adverse events according to CD4R cell count group at start of combination antiretroviral
therapy.All univariable estimates adjusted for centre due to differences in testing practices. (a)Multivariablemodel adjusted for viral
load, ART regimen, HBV coinfection, HCV coinfection, age, exposure, time on ART, centre. (b) Multivariable model adjusted for
viral load, ART regimen,HBV coinfection,HCVcoinfection, sex, ethnicity, time onART, centre. (c)Multivariablemodel adjusted for
viral load, antiretroviral regimen, ethnicity, age, centre. (d) Multivariable model adjusted for viral load, ART regimen, time on ART,
exposure, age, centre. (e) Multivariable model adjusted for viral load, ART regimen, HBV coinfection, HCV coinfection, exposure,
time on ART, centre. ART, antiretroviral therapy; CI, confidence interval; LDAE, laboratory-defined adverse event.individual risk of ART-related adverse events must
be evaluated in the context of the potential benefits
for that individual, considering comorbidities, age,
sexual practices and long-term prognosis. Although
we await evidence from ongoing RCTs regardingCopyright © Lippincott Williams & Wilkins. Unautthe potential risks and benefits of ART initiation
with CD4þ cell counts at least 500 cells/ml, the
potential for added adverse events in starting ART at
high CD4þ cell counts must remain a key discussion
with patients.horized reproduction of this article is prohibited.
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